CS
COGT icon

Credit Suisse’s Cogent Biosciences COGT Stock Holding History

Credit Suisse’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$425K Hold
63,289
– – ﹤0.01% 2703
2023
Q4 		$372K Sell
63,289
-20,489
-24% -$157K ﹤0.01% 2857
2023
Q3 		$817K Buy
83,778
+4,201
+5% +$49.8K ﹤0.01% 2413
2023
Q2 		$942K Buy
79,577
+50,887
+177% +$584K ﹤0.01% 2418
2023
Q1 		$310K Buy
28,690
+2,702
+10% +$34.6K ﹤0.01% 2984
2022
Q4 		$300K Buy
25,988
+25,626
+7,079% +$318K ﹤0.01% 3041
2022
Q3 		$5K Buy
362
+320
+762% +$4.39K ﹤0.01% 3645
2022
Q2 		$0 Buy
+42
New +$287 ﹤0.01% 3983

Other funds holding COGT

KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Credit Suisse's COGT Position: Q1 2024 in Review

Credit Suisse held its Cogent Biosciences (COGT) position steady in Q1 2024 at 63,289 shares worth $425K. The position accounts for ﹤0.01% of the portfolio, ranked #2703.

Credit Suisse first reported a position in COGT in Q2 2022 and has held it in 8 quarters since. The position peaked at $942K in Q2 2023. 146 funds tracked by Wall St. Rank hold COGT as of Q1 2024.

  • Credit Suisse held 63,289 shares of Cogent Biosciences worth $425K as of Q1 2024.
  • Credit Suisse left its Cogent Biosciences share count unchanged in Q1 2024.
  • Cogent Biosciences made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2703 holding.
  • Credit Suisse first reported a position in Cogent Biosciences in Q2 2022 and has held it in 8 quarters since.
  • Credit Suisse's Cogent Biosciences position peaked at $942K in Q2 2023.
  • 146 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.